1613220‑15‑7, Niraparib Tosylate Monohydrate (MK‑4827): The Latest News | ANQING CHICO PHARMACEUTICAL CO., LTD.
AbstractNiraparib (Zejula®, MK‑4827) is a once-daily oral PARP inhibitor first approved in March 2017 (US) and November 2017 (EU) for maintenance treatment in ovarian cancer. Developed by Tesaro (now part of GSK), it selectively inhibits PARP‑1 and PARP‑2, interfering with DNA repair. Approvals have expanded to first-line and platinum-sensitive maintenance settings. Global sales rose from approximately US$539 M in 2020 to an estimated US$720 M in 2023, with US$810 M projected for 2024. Niraparib maintains a solid share in the PARP market but now faces competition from other inhibitors and branded combination products like Akeega. Patent expiry around 2028 may trigger generic entry. Recent news includes strategic royalty rulings and expanded combinations.
Niraparib; PARP inhibitor; ovarian cancer; global sales; market competition; Akeega; patent
Niraparib inhibits PARP‑1/2, inducing synthetic lethality in tumor cells, especially those with DNA repair deficiencies. It gained swift approval following strong NOVA Phase III results in recurrent ovarian cancer .
CAS: 1613220‑15‑7
Synonym: MK‑4827 (niraparib tosylate monohydrate)
Formula: C₂₆H₂₈N₄O₄S
MRW: 492.59
Appearance: White to off-white solid
Solubility: High in DMSO; moderate in ethanol.
Originally discovered by Merck, licensed to Tesaro in 2012. Key clinical trials:
NOVA (germline and non‑germline BRCA recurrent ovarian cancer)
PRIME and others expanding first-line maintenance
US FDA: March 27, 2017 – maintenance after platinum response
EU EMA: November 16, 2017
Expanded to first-line maintenance (Apr 2020) and HRD-positive settings, including mCRPC combo approval for Akeega (Aug 2023)
| Year | Global Sales |
|---|---|
| 2020 | 539¹ |
| 2021 | 610² |
| 2022 | 660 |
| 2023 | 720 |
| 2024 | 810 (projected; +12%) |
1 Based on GSK’s 2022 Q1 data: £339 M (~US$539 M) (dataintelo.com, finance.ifeng.com).
2 Growth tracking between 2020–2023 suggests approximately +13% CAGR. Additional forecast data supports ~US$810 M in 2024 .
In 2023, North America led (~45%), followed by Europe (25%) and Asia‑Pacific (20%) (verifiedmarketreports.com).
Competing PARP inhibitors: olaparib, rucaparib, talazoparib.
Market share supported by combination labels like Akeega (niraparib + abiraterone), EU/US approvals in Aug 2023
Patent protection expected until ~2028; generic entry after likely to pressure pricing .
Patent Rule: GSK required to pay royalties to AstraZeneca for Zejula sales based on a ruling
Market Growth: PARP inhibitor market valued at ~US$6.3 Bn in 2024, growing at ~8.7% CAGR; niraparib is a key player
Overall PARP inhibitors expected to reach US$16 Bn by 2034
Niraparib sales continue robustly, but future forces include:
First-line indication expansion
Jan combination therapy uptake
Patent expiry and generics entry post-2028
Regulatory and clinical data
Sales and market data (GSK reports, forecasts)
Market valuations and competition
Active Pharmaceutical Ingredient
1613220-15-7,Niraparib Tosylate Monohydrate,(chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
References or other information:
FDA,Wikipedia,Chatgpt,DeepSeek,chemicalbook,lookchem.
If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.
